William Blair is the bookrunning manager; Craig-Hallum Capital assists
By Devika Patel
Knoxville, Tenn., Aug. 15 – NeoGenomics, Inc. said it priced its $32.2 million public sale of stock with a $4.83 million greenshoe. The deal was announced Thursday.
The company will sell 7 million common shares at $4.60 apiece. The per-share purchase price is a 5.74% discount to the closing share price of $4.88 on Aug. 14.
William Blair & Co., LLC is the bookrunner.
Settlement is expected Aug. 20.
Proceeds will be used for working capital, capital expenditures and other corporate purposes, including potential acquisitions and debt repayment.
Based in Fort Myers, Fla., NeoGenomics is a cancer genetics diagnostics testing company.
| Issuer: | NeoGenomics, Inc.
|
| Issue: | Common stock
|
| Amount: | $32.2 million
|
| Greenshoe: | $4.83 million
|
| Shares: | 7 million
|
| Price: | $4.60
|
| Warrants: | No
|
| Bookrunner: | William Blair & Co., LLC
|
| Co-lead manager: | Craig-Hallum Capital Group LLC
|
| Co-managers: | Stephens Inc., Roth Capital Partners, LLC, Sidoti & Co., LLC and Dawson James Securities, Inc.
|
| Announcement date: | Aug. 14
|
| Pricing date: | Aug. 15
|
| Settlement date: | Aug. 20
|
| Stock symbol: | Nasdaq: NEO
|
| Stock price: | $4.88 at close Aug. 14
|
| Market capitalization: | $251.37 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
